Phenyl-oxazoles, a new family of inverse agonists at the H3 histamine receptor

ChemMedChem

Volumn 5, Issue 2, 2010, Pages 206-212

  Denonne, Frédéric ^a   Atienzar, Franck ^a   Célanire, Sylvain ^a,b   Christophe, Bernard ^a,b   Delannois, Frédérique ^a   Delaunoy, Christel ^a   Delporte, Marie Laure ^a   Durieu, V́ronique ^a   Gillard, Michel ^a   Lallemand, B́ńdicte ^a   Lamberty, Yves ^a   Lorent, Genevíve ^a   Vanbellinghen, Alain ^a   Van Houtvin, Nathalie ^a   Verbois, Vaĺrie ^a   Provins, Laurent ^a  

^a UCB PHARMA   (Belgium)

^b ADDEX PHARMACEUTICALS   (Switzerland)

Author keywords

Biological activity; Cognitive disorders; Histamine; Receptors; Structure activity relationships

Indexed keywords

ALPHA METHYLHISTAMINE; HISTAMINE H3 RECEPTOR AGONIST; OXAZOLE DERIVATIVE;

ACIDITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SYNTHESIS; FEMALE; GUINEA PIG; MALE; MAXIMUM PLASMA CONCENTRATION; MYENTERIC PLEXUS; NONHUMAN; PLASMA CLEARANCE; POLYMERIZATION; PRIORITY JOURNAL; RAT; RING OPENING;

ANIMALS; BENZENE; CACO-2 CELLS; CELL LINE; COGNITION DISORDERS; DRUG INVERSE AGONISM; HISTAMINE ANTAGONISTS; HUMANS; MALE; MICE; MICROSOMES, LIVER; OXAZOLES; PYRROLIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, HISTAMINE H3; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

EID: 75749129008     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.200900446     Document Type: Article

References (38)

1. G. Barger, H. H. Dale, J. Physiol. 1910, 41, 19-59.
2. W. Black, W. A. M. Duncan, G. J. Durant, C. R. Ganellin, M. E. Parsons, Nature 1972, 236, 385.
3. a) J. M. Monti, Life Sci. 1993, 53, 1331-1338;
4. b) D. Vohora, IDrugs 2004, 7, 667-673;
5. c) M. B. Passani, P. Blandina, Curr. Med. Chem. CNS Agents 2004, 4, 17-26;
6. d) S. Ćlanire, F. Lebon, H. Stark in The Third Histamine Receptor: Selective ligands as potential therapeutic agents in CNS disorders, (Ed.: D. S. Vohora), Taylor & Francis, CRC Press, Boca Raton, 2008, pp. 103-165 and references therein;
7. e) K. Sander, T. Kottke, H. Stark, Biol. Pharm. Bull. 2008, 31, 2163-2181;
8. f) M. Wijtmans, R. Leurs, I. de Esch, Expert Opin. Invest. Drugs 2007, 16, 967-985;
9. g) S. Celanire, M. Wijtmans, P. Talaga, R. Leurs, I. J. P. de Esch, Drug Discovery Today 2005, 10, 1613-1627;
10. h) R. Leurs, R. A. Bakker, H. Timmerman, I. J. de Esch, Nat. Rev. Drug Discovery 2005, 4, 107-120.
11. H. D. Lim, R. A. Smits, R. Leurs, I. J. de Esch, Curr. Top. Med. Chem. 2006, 6, 1365-1373;
12. R. L. Thurmond, E. W. Gelfand, P. J. Dunford, Nat. Rev. Drug Discovery 2008, 7, 41-53.
13. T. W. Lovenberg, B. L. Roland, S. J. Wilson, X. Jiang, J. Pyati, A. Huvar, M. R. Jackson, M. G. Erlander, Mol. Pharmacol. 1999, 55, 1101-1107.
14. http://www.pfizer.com, Pfizer pipeline.
15. Sanofi-Aventis, 1st quarter 2009 financial results.
16. http://www.gsk.com, product pipeline.
17. http://clinicaltrials.gov/; ref. number: NCT00880217.
18. http://clinicaltrials.gov/; ref. number: NCT00642993.
19. http://clinicaltrials.gov/; ref. number: NCT00690274.
20. http://clinicaltrials.gov/; ref. number: NCT00366080.
21. E. Tiligada, E. Zampeli, K. Sander, H. Stark, Expert Opin. Invest. Drugs 2009, 18, 1519-1531.
22. S. Célanire, B. Christophe, P. Collart, I. de Esch, D. Dassesse, C. Delaunoy, F. Denonne, V. Durieu, M. Gillard, B. Lallemand, Y. Lamberty, F. Lebon, J.-M. Nicolas, L. Qúré, A. Vanbellinghen, N. Van houtvin, V. Verbois, M. Wijtmans, H. Timmerman, P. Talaga, R. Leurs, and L. Provins, ChemMedChem 2009, 4, 1063-1068.
23. For a glimpse at oxazoline metabolism, see L. B. Turnbull, C. P. Johnson, Y. H. Chen, L. F. Sancilio, R. B. Bruce, J. Med. Chem. 1974, 17, 45-48.
24. L. S. Beavers, S. L. Boulet, T. P. Finn, R. A. Gadski, W. J. Hornback, C. D. Jesudason, R. T. Pickard, F. C. Stevens, G. M. Vaught, (Eli Lilly & Co.), WO2006019833, 2006.
25. For detailed synthetic procedures, see: S. Célanire, F. Denonne, (UCB Pharma, S.A.), WO2006103045, 2006.
26. 3 histamine receptors as described in: T. R. Miller, J. L. Baranowski, B. R. Estvander, D. G. Witte, T. L. Carr, A. M. Manelli, K. M. Krueger, M. D. Cowart, J. D. Brioni, T. A. Esbenshade, Assay Drug Dev. Technol. 2008, 6, 339-349.
27. G. K. Menkveld, H. Timmerman, Eur. J. Pharmacol. 1990, 186, 343-347.
28. W. A. Daniel, Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2003, 27, 65-73.
29. a) R. A. Bevins, J. Besheer, Nat. Protoc. 2006, 1, 1306-1311;
30. b) X. Ligneau, D. Perrin, L. Landais, J.-C. Camelin, T. P. G. Calmels, I. Berrebi-Bertrand, J.-M. Lecomte, R. Parmentier, C. Anaclet, J.-S. Lin, V. Bertaina-Anglade, C. Drieu la Rochelle, F. d'Aniello, A. Rouleau, F. Gbahou, J.-M. Arrang, C. R. Ganellin, H. Stark, W. Schunack, J.-C. Schwartz, J. Pharmacol. Exp. Ther. 2006, 320, 365-375.
31. J. C. Dodart, C. Mahis, A. Ungerer, Neuroreport 1997, 8, 1173-1178.
32. W. M. Westerink, J. C. Stevenson, A. Lauwers, G. Griffioen, G. J. Horbach, W. G. Schoonen, Mutat. Res. 2009, 676, 113-130.
33. 3R affinities have not been measured but there is 98% homology between the receptors of the two species: J. Chen, C. Liu, T. W. Lovenberg, Eur. J. Pharmacol. 2003, 467, 57-65.
34. A. W. Knight, N. Billinton, P. A. Cahill, A. Scott, J. S. Harvey, K. J. Roberts, D. J. Tweats, P. O. Keenan, R. M. Walmsley, Mutagenesis 2007, 22, 409-416.
35. N. Flamand, J. Meunier, P. Meunier, C. Agapakis-Caussé, Toxicol. in vitro 2001, 15, 105-114.
36. 3R is 25 nm. It has not been measured on mice.
37. Z. Zhou, Q. Gong, Z. Fan, J. C. Makielski, G. A. Robertson, Biophys. J. 1998, 74, 230- 241.
38. 50 value falls within the range of active doses in the novel object recognition test.